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Editorial
Misconceptions and ill-founded theories can arise in all areas of science. However, the apparent accessibility of many epidemiology
findings and popular interest in the subject can lead to additional misunderstandings. The article below is the third in an occasional
series of short editorials highlighting some current misinterpretations of epidemiological findings. Invited authors will be given wide
scope in judging the prevalence of the misconception under discussion. We hope that this series will prove instructive to cancer
researchers in other disciplines as well as to students of epidemiology.
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For breast cancer, as for many other diseases, treatment that is
appropriate for one patient may be inappropriate for another.
Ideally, therefore, what is wanted from trials is not only an answer
to the question ‘Is this treatment helpful on average for a wide
range of patients?’, but also an answer to the question ‘For which
recognisable categories of patient is this treatment particularly
helpful?’ (EBCTCG, 2005a,b)
In general, however, this ideal cannot be achieved directly from
subgroup-specific analyses of clinical trial results because apparent
differences between the proportional risk reductions in different
subgroups of the patients in a trial (or even in a meta-analysis of
many trials) are often surprisingly unreliable. For example, even if
the proportional effects of the trial treatment in specific subgroups
really are importantly different, standard subgroup analyses are so
insensitive that they may well fail to demonstrate these real
differences. Conversely, even if the trial results suggest that the
trial treatment works in some subgroups but not in others (thereby
giving the appearance of a ‘qualitative interaction’), this may still
not be good evidence for subgroup-specific treatment preferences.
The play of chance often produces qualitatively wrong answers in
particular subgroups in trials (or in meta-analyses of trials) that
could, if interpreted incautiously, lead to millions of people being
treated inappropriately or untreated inappropriately.
Questions about such ‘interactions’ between patient character-
istics and the effects of treatment are easy to ask, but are
surprisingly difficult to answer reliably. Apparent interactions can
often be produced by the play of chance and, in particular
subgroups, can mimic or obscure some of the moderate treatment
effects that might realistically be expected. To illustrate this, a
subgroup analysis was performed based on the astrological birth
signs of 17000 patients in the Second International Study of Infarct
Survival (ISIS-2), a randomised trial of 1 month of daily aspirin vs
placebo for suspected acute myocardial infarction. Overall in this
trial, the 1-month survival advantage produced by aspirin was
demonstrated conclusively (804 vascular deaths among 8587
patients allocated aspirin vs 1016 among 8600 allocated no aspirin;
23% proportional reduction, Po0.000001). To demonstrate the
unreliability of subgroup analyses, these findings were subdivided
into 12 subgroups according to the patients’ medieval astrological
birth signs; the results in each were examined to find which of the
12 appeared least promising, and when just those with apparently
unpromising results were collected together, it was ‘discovered’
that aspirin appeared totally ineffective for patients born under
Libra or Gemini (Table 1) (ISIS, 1988)!
It would be unwise to conclude from such a result that patients
born under the astrological birth sign of Libra or Gemini should
not be given aspirin if they have a heart attack. However, similar
conclusions based on ‘exploratory’ data-derived subgroup ana-
lyses, which from a purely statistical viewpoint are no more
reliable than these astrological subgroup analyses, are often
reported and believed, with inappropriate effects on worldwide
clinical practice.
There are three partial remedies for this unavoidable conflict
between the reliable subgroup-specific conclusions that doctors
and patients want and need, and the statistically unreliable
findings that direct subgroup-specific analyses can usually offer.
However, the extent to which these remedies are helpful in
particular instances is one on which informed judgements differ.
First, where there are good prior reasons for anticipating that
the proportional effects of treatment might be very different in
different circumstances, one particular subgroup analysis may be
prespecified in the study protocol, along with a prediction of the
direction of the proposed interaction. (For example, it was
expected that the benefits of fibrinolytic therapy for acute
myocardial infarction would be greater the earlier such patients
were treated, and so some studies prespecified that the statistical
analyses would be subdivided by the number of hours from the
onset of symptoms to treatment: FTT, 1994.) Although a single
prespecified subgroup-specific analysis can then be taken some-
what more seriously than other subgroup analyses, protocols that
pre-specify several subgroup analyses as ‘secondary outcomes’ can
yield importantly wrong answers. *Correspondence: Professor R Peto; E-mail: secretary@ctsu.ox.ac.uk
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that is suggested by the overall results of the trial (or, better still, by
the overall results from a meta-analysis of all such trials) as a semi-
quantitative guide to the proportional risk reductions in various
specific subgroups of patients, giving little weight to the apparent
results in each of such subgroups. This is clearly the right way to
interpret the astrological ‘findings’ in Table 1, and, if used sensibly,
may also in many other circumstances provide the best guide as to
whether one treatment is better than another in particular subgroups.
The main determinant of whether toxic or expensive
treatment is worthwhile is the absolute risk reduction that it
produces, and it is perfectly proper to use the fact that patients
who already have a very good prognosis anyway and are at low
absolute risk cannot have a large absolute benefit (for, even if a
small risk is halved the absolute benefit is small). Classification of
patients as being at low (or high) risk of an adverse outcome is
often a useful guide as to which patients can expect a small
(or large) absolute gain. Appropriate clinical use of this low-risk/
high-risk split may not require support from formal subgroup
analyses – indeed, it could even be damaged by incautious reliance
on such analyses.
The third approach is to be influenced, in discussing the likely
effects on mortality in specific subgroups of breast cancer patients,
not only by mortality analyses but also by analyses of recurrence,
early recurrence, local recurrence or some other major ‘surrogate’
outcome. For, if the overall results are similar but much more
highly significant for recurrence than for mortality, subgroup
analyses with respect to the former may be more stable and may
provide a better guide as to whether there are any major
differences between subgroups in the proportional risk reduction
produced by treatment (EBCTCG, 2005a,b).
The appropriate interpretation of apparently different results in
different subgroups of trial results is still one of the most difficult
matters of judgement in the interpretation of randomised
evidence; at present, many clinicians and regulatory agencies pay
far too much attention to irregularities between the apparent
effects in different subgroups, to the potential detriment of the care
of individual patients.
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Table 1 False-negative mortality effect in a subgroup defined only by the
medieval astrological birth sign: the ISIS-2 trial of aspirin among over 17000
patients with acute myocardial infarction
Astrological
birth sign
No. of 1-month deaths
(aspirin vs placebo)
Statistical
significance
Libra or Gemini 150 vs 147 NS
All other signs 654 vs 869 2Po0.000001
Any birth sign
a 804 (9.4%) vs 1016 (11.8%) 2Po0.000001
aAppropriate overall analysis for assessing the true effect in all subgroups. Astrology
divides birth dates into 12 ‘birth signs’ (which depend only on the day and month of
birth, not the year of birth). To demonstrate the potential unreliability of subgroup
analyses, the ISIS-2 patients were divided into 12 subgroups according to their
astrological birth sign, and the apparent effects of aspirin were calculated separately in
each of these 12 subgroups. Because of the play of chance, the apparent effects
differed from one subgroup to another, ranging from no apparent effect of aspirin in
two subgroups (Libra and Gemini) to aspirin apparently halving the mortality in
another (Capricorn).
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